Abstract
Introduction
Poland' s economy has grown from strength to strength in the past 5 years, and
despite the global economic downturn Poland is expected to maintain positive
growth through 2010. However, concern exists over intellectual property and
inconsistent drug reimbursement. Nevertheless the strong growth of the
hospital and retail sectors is encouraging for both foreign and domestic
Pharma.
Scope of this research
- Provides an overview of the evolving demographics of Poland
- In-depth assessment of its healthcare and regulatory system and the
challenges that branded Pharma face
- Insight into of the competitive dynamics of both the hospital and retail
markets
- Profiles and analysis of key brands and players in the Polish market
Research and analysis highlights
The Polish government is undertaking structural reforms with the aid of EU
funding to improve internal infrastructure in an effort to attract more
foreign investment. However, Poland needs to address its regulatory process
and get up to speed both implementing and enforcing EU pharmaceutical
legislation.
The cardiovascular and central nervous system markets in addition to those for
other chronic diseases are forecast to experience significant further growth
driven by the growing prevalence of these diseases among the increasingly
aging population.
The growth of the Polish oncology hospital market is in part attributed to the
significant funding this area has received from the government, with other
chronic diseases expected to benefit as the government expands its therapeutic
programs into other areas.
Key reasons to purchase this research
- Understand the Polish healthcare market and the strategic implications of
future reforms and how these will affect your business
- Identify the opportunities ad barriers for entering the Polish market,
plus growth drivers and resistors for established domestic and foreign players
- Gain insight into the evolving dynamics of the Polish retail and hospital
pharmaceutical market
| 
View Cart
